<DOC>
	<DOCNO>NCT00043108</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Giving combination chemotherapy radiation therapy surgery may shrink tumor remove surgery may kill remain tumor cell follow surgery . PURPOSE : Phase II trial study effectiveness combine paclitaxel carboplatin radiation therapy surgery treat patient newly diagnose locally advanced non-small cell lung cancer .</brief_summary>
	<brief_title>Combination Chemotherapy , Surgery , Radiation Therapy Treating Patients With Non-Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Determine complete resection rate toxic death rate patient locally advance non-small cell lung cancer treat paclitaxel , carboplatin , radiotherapy follow surgical resection adjuvant paclitaxel carboplatin . - Determine survival , event-free survival , incidence pathologic complete remission patient treat regimen . - Determine protocol completion rate ( CR ) patient treat regimen . - Determine feasibility toxicity regimen patient . - Determine pathologic response rate/downstaging , pathologic near CR rate , freedom distant metastasis rate , freedom local regional failure rate patient treat regimen . OUTLINE : Patients receive induction therapy comprise radiotherapy 5 day week 5.5-6 week paclitaxel IV 1 hour carboplatin IV 30 minute day 1 , 8 , 15 , 22 , 29 , 36 . Within 1-3 week completion induction therapy , patient undergo restaging . Patients resectable disease undergo surgical resection within 4-8 week induction therapy . Patients unresectable disease undergo additional radiotherapy 5 day week 3 week receive paclitaxel carboplatin induction therapy day 1 , 8 , 15 . Within 4-12 week surgery additional chemoradiotherapy , patient receive adjuvant therapy comprise paclitaxel carboplatin induction therapy day 1 . Adjuvant treatment repeat every 4 week 3 course . Patients follow every 3 month 2 year , every 6 month 3 year , annually thereafter . PROJECTED ACCRUAL : Approximately 57 patient accrue study within 4 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm , newly diagnose , unilateral primary nonsmall cell lung cancer ( NSCLC ) Must involvement superior sulcus , chest wall , mediastinum Must least 1 follow : Locally advance Pancoast tumor document mediastinal supraclavicular nodal involvement ( T3T4 , N01 ) Resectable chest wall disease ( T3 , N01 ) Marginally resectable T4 , N01 , NX central NSCLC N2 patient potentially resectable induction chemoradiotherapy No evidence extrathoracic spread liver , adrenal , brain , bone No evidence supraclavicular node , malignant pleural pericardial effusion , distant metastasis PATIENT CHARACTERISTICS : Age 18 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Absolute neutrophil count least 2,000/mm^3 Platelet count least 100,000/mm^3 Hepatic Bilirubin great 1.5 mg/dL SGOT great 3 time upper limit normal Renal Creatinine great 2.0 mg/dL Cardiovascular No superior vena cava syndrome No myocardial infarction within past 6 month No active uncontrolled congestive heart failure No active uncontrolled arrhythmia within past 6 month Pulmonary FEV1 least 800 mL Other No active invasive malignancy require therapy within past 2 year No ongoing need adjuvant therapy Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception least 3 month study entry PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy No prior pelvic thoracic radiotherapy Surgery See Disease Characteristics Other Concurrent beta blocker , digitalis derivative , channelblocking agent allow provided cardiac condition stable</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>stage II non-small cell lung cancer</keyword>
	<keyword>stage IIIA non-small cell lung cancer</keyword>
	<keyword>stage IIIB non-small cell lung cancer</keyword>
</DOC>